Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 23.89% is 45% above its 5-year average of 16.45%, near the high end of its 5-year range (10.45%–23.89%).
13.52% above its 12-month average of 21.05%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 5.90%.
RETURN ON ASSETS (ROA)
23.89%
RETURN ON ASSETS (ROA) AVG TTM
21.05%
RETURN ON ASSETS (ROA) AVG 3Y
19.32%
RETURN ON ASSETS (ROA) AVG 5Y
16.45%
RETURN ON ASSETS (ROA) AVG 10Y
10.88%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+13.52%
CURRENT VS 3Y AVG
+23.62%
CURRENT VS 5Y AVG
+45.21%
CURRENT VS 10Y AVG
+119.61%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+364.79%
vs the sector median at left
Medpace Holdings, Inc.
Market Cap
$16.76B
Return on Assets (ROA)
23.89%
TTM Avg
21.05%
3Y Avg
19.32%
5Y Avg
16.45%
Market Cap
$15.73B
Return on Assets (ROA)
10.07%
TTM Avg
7.10%
3Y Avg
8.43%
5Y Avg
7.35%
Market Cap
$15.21B
Return on Assets (ROA)
1.97%
TTM Avg
2.19%
3Y Avg
1.89%
5Y Avg
3.83%
Market Cap
$18.71B
Return on Assets (ROA)
3.54%
TTM Avg
3.64%
3Y Avg
3.29%
5Y Avg
2.38%
Market Cap
$19.16B
Return on Assets (ROA)
-1.17%
TTM Avg
-5.49%
3Y Avg
-1.68%
5Y Avg
-1.68%
Market Cap
$13.97B
Return on Assets (ROA)
34.50%
TTM Avg
22.59%
3Y Avg
17.42%
5Y Avg
13.40%
Market Cap
$13.17B
Return on Assets (ROA)
-3.17%
TTM Avg
-0.94%
3Y Avg
2.58%
5Y Avg
3.75%
Market Cap
$12.56B
Return on Assets (ROA)
8.13%
TTM Avg
5.32%
3Y Avg
4.08%
5Y Avg
2.47%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $16.76B | 23.89% | 21.05% | 19.32% | 16.45% |
| Solventum Corporation (SOLV)vs › | $15.73B | 10.07% | 7.10% | 8.43% | 7.35% |
| Revvity, Inc. (RVTY)vs › | $15.21B | 1.97% | 2.19% | 1.89% | 3.83% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.71B | 3.54% | 3.64% | 3.29% | 2.38% |
| Viatris Inc. (VTRS)vs › | $19.16B | -1.17% | -5.49% | -1.68% | -1.68% |
| Exelixis, Inc. (EXEL)vs › | $13.97B | 34.50% | 22.59% | 17.42% | 13.40% |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.17B | -3.17% | -0.94% | 2.58% | 3.75% |
| STERIS plc (STE)vs › | $20.66B | 7.50% | 6.68% | 4.44% | 4.33% |
| Penumbra, Inc. (PEN)vs › | $12.56B | 8.13% | 5.32% | 4.08% | 2.47% |
| DaVita Inc. (DVA)vs › | $12.21B | 4.79% | 4.84% | 4.27% | 4.56% |
ROA
23.9%
ROE
113.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 22.84% |
| 2024-12-31 | 19.25% |
| 2023-12-31 | 17.07% |
| 2022-12-31 | 18.14% |
| 2021-12-31 | 10.96% |
| 2020-12-31 | 10.45% |
| 2019-12-31 | 8.79% |
| 2018-12-31 | 7.56% |
| 2017-12-31 | 4.11% |
| 2016-12-31 | 1.37% |
| 2015-12-31 | -0.88% |
| 2014-12-31 | -1.42% |
| 2013-12-31 | 0.00% |
